Evidence map›Paper›PMID 40646294›Full record

ArticleClinical and experimental medicine2025

Autoantibody profiling using microarray identifies biomarkers associated with chemoimmunotherapy efficacy and immune-related adverse events in lung cancer patients.

Zuo Wang, Bomiao Yu, Shuaifeng Guo, Qiuchi Chen, Xiaomei Zhang, Ran Zhang, Yongle Fan, Jia Lv, Yang Dong, Qian Niu and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Zuo Wang *School of Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
Bomiao Yu *State Key Laboratory of Medical Proteomics, National Center for Protein Sciences-Beijing (PHOENIX Center), Beijing Proteome Research Center, Beijing Institute of Lifeomics, Beijing, 102206, China.
Shuaifeng Guo *School of Basic Medical Sciences, Anhui Medical University, Hefei, 230032, China.
Qiuchi Chen *Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Xiaomei ZhangState Key Laboratory of Medical Proteomics, National Center for Protein Sciences-Beijing (PHOENIX Center), Beijing Proteome Research Center, Beijing Institute of Lifeomics, Beijing, 102206, China.
Ran ZhangState Key Laboratory of Medical Proteomics, National Center for Protein Sciences-Beijing (PHOENIX Center), Beijing Proteome Research Center, Beijing Institute of Lifeomics, Beijing, 102206, China.
Yongle FanState Key Laboratory of Medical Proteomics, National Center for Protein Sciences-Beijing (PHOENIX Center), Beijing Proteome Research Center, Beijing Institute of Lifeomics, Beijing, 102206, China.
Jia LvProteomicsEra Medical Co., Ltd, Beijing, 102206, China.
Yang DongProteomicsEra Medical Co., Ltd, Beijing, 102206, China.
Qian NiuProteomicsEra Medical Co., Ltd, Beijing, 102206, China.
Xiaohan ZhangState Key Laboratory of Medical Proteomics, National Center for Protein Sciences-Beijing (PHOENIX Center), Beijing Proteome Research Center, Beijing Institute of Lifeomics, Beijing, 102206, China.
Yongmei LiuDepartment of Clinical Laboratory, State Key Laboratory of Complex, Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
Lu ChenDepartment of Laboratory Medicine, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing, China.
Ying WuAcupuncture Department, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing, China.
Xingming XuState Key Laboratory of Medical Proteomics, National Center for Protein Sciences-Beijing (PHOENIX Center), Beijing Proteome Research Center, Beijing Institute of Lifeomics, Beijing, 102206, China.
Ruimin LiuState Key Laboratory of Medical Proteomics, National Center for Protein Sciences-Beijing (PHOENIX Center), Beijing Proteome Research Center, Beijing Institute of Lifeomics, Beijing, 102206, China.
Yuxin JiaoState Key Laboratory of Medical Proteomics, National Center for Protein Sciences-Beijing (PHOENIX Center), Beijing Proteome Research Center, Beijing Institute of Lifeomics, Beijing, 102206, China.
Di HuProteomicsEra Medical Co., Ltd, Beijing, 102206, China.
Yan JiaProteomicsEra Medical Co., Ltd, Beijing, 102206, China.
Bingwei WangSchool of Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China. bingweiwang@njucm.edu.cn.
Zheng CaoDepartment of Laboratory Medicine, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing, China. zhengcao2011@ccmu.edu.cn.
Qiaoyun TanCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. tanqiaoyun@hust.edu.cn.
Xiaobo YuSchool of Basic Medical Sciences, Anhui Medical University, Hefei, 230032, China. yuxiaobo@ncpsb.org.cn.

Funding

Beijing Municipal Natural Science Foundation L234034, M23010Beijing Xisike Clinical Oncology Research Foundation Y-Young2023-0125Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine ZYYCXTD-C-202204Municipal International Cooperation and Exchange Project Z231100002723004National Key Research and Development Program of China 2024YFA1307600, 2024YFA1307601, 2024YFA1307604, 2022YFE0210400, 2021YFA1301604National Natural Science Foundation of China 82200212State Key Laboratory of Proteomics SKLP-O202007State Key Laboratory of Proteomics SKLP-O202205
6 · The paper itself

Abstract

Autoimmune disease associated autoantibodies have been implicated in both immune-related adverse events (irAEs) and chemoimmunotherapy responses; however, current biomarkers lack sufficient predictive power, especially for irAEs severity. Here, we developed an autoimmune disease (AID) autoantigen microarray (AID microarray) capable of detecting 125 autoantibodies associated with over 30 autoimmune diseases. The AID microarray demonstrated excellent reproducibility (intra-batch correlation: 0.99; inter-batch correlation: 0.97) and strong concordance with clinical chemiluminescence immunoassays (R

Indexed as

AutoantibodiesImmune Checkpoint InhibitorsImmunotherapyLung NeoplasmsAgedAged, 80 and overBiomarkersBiomarkers, TumorFemaleHumansMaleMicroarray AnalysisMiddle AgedAutoantibodiesBiomarkersBiomarkers, TumorImmune Checkpoint InhibitorsAutoantibodyChemoimmunotherapyImmune-related adverse eventsLung cancerMicroarray

Identifiers

PMID40646294
PMCPMC12254182

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.